Lipid‐lowering therapy in patients with type 2 diabetes: the case for early intervention
- 13 February 2008
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 24 (4), 286-293
- https://doi.org/10.1002/dmrr.806
Abstract
Chronic complications of type 2 diabetes, in particular, macrovascular complications, confer substantial morbidity and mortality and adversely affect a patient's quality of life. Early intensive intervention to control cardiovascular risk factors is essential in clinical management. Atherogenic dyslipidaemia characterized by elevated triglycerides, a low level of high‐density lipoprotein cholesterol (HDL‐C), and an increase in the preponderance of small, dense low‐density lipoprotein (LDL) particles, is a key modifiable risk factor for macrovascular diabetic complications. Lowering low‐density lipoprotein cholesterol (LDL‐C) with a statin (or the combination of statin and ezetimibe) is the main focus for reducing cardiovascular risk in patients with diabetes. However, statins fail to address the residual cardiovascular risk associated with low HDL‐C. Fibrates are effective against all components of the atherogenic dyslipidaemia associated with type 2 diabetes. Secondary analyses of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study suggest a role for early treatment with fenofibrate in improving cardiovascular risk reduction in type 2 diabetes and provide safety data supporting the use of fenofibrate in combination with a statin. Data from the FIELD study suggest that fenofibrate may also have potential to impact on microvascular diabetic complications associated with type 2 diabetes. Data are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study to evaluate the outcome benefits of combining fenofibrate with a statin in patients with type 2 diabetes. Finally, in view of divergent study results and outstanding data, assessment of the risk of the individual with type 2 diabetes is mandatory to assist clinical decision‐making when initiating lipid therapy. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 44 references indexed in Scilit:
- Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trialsBMJ, 2006
- Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)American Journal of Kidney Diseases, 2005
- Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 DiabetesDiabetes Care, 2005
- The Role of Lipids in the Development of Diabetic Microvascular ComplicationsAmerican Journal of Cardiovascular Drugs, 2003
- Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)Jama-Journal Of The American Medical Association, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Jama-Journal Of The American Medical Association, 2001
- Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrateDiabetes/Metabolism Research and Reviews, 1999
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurementsJournal of Clinical Periodontology, 1988
- Lipids, diabetes, and coronary heart disease: Insights from the Framingham StudyAmerican Heart Journal, 1985